Vivos to Present at 2018 National Investment Bankers Association (NIBA) New York City Meeting

NIBA brings together innovative companies with the investment community

 

DENVER (March 19, 2018) – Vivos Therapeutics, a world leader in the treatment of obstructive sleep apnea (OSA), announced today that it will be a featured presenter at the March 26 – 27 National Investment Bankers Association (NIBA) conference, to be held in New York City at the Westin Hotel in Times Square.

Vivos is successfully deploying a highly effective, interdisciplinary clinical treatment for sufferers of mild to moderate obstructive sleep apnea (OSA), featuring its proprietary line of unique oral appliances. While an estimated 29 million adults are suffering daily from the wide range of negative impacts of this condition, another 22 million children may also be at risk. Though it occurs across all age groups and genders, it is more common in men, particularly middle aged and overweight men. Overall, approximately one in every seven Americans suffers directly from sleep apnea.

Presenting the unique Vivos story will be R. Kirk Huntsman, chief executive officer at Vivos, and Ed Loew, who serves as senior vice president, capital markets and investor relations.

The Vivos System is a breakthrough technology and treatment for OSA and may be the first viable long-term solution to address a major root cause of the condition: an underdeveloped or obstructed airway. While the vast majority of OSA solutions treat the symptoms through either pressure or force, the Vivos appliance gently remodels the upper airway by gradually developing/repositioning the jaws, thus restoring healthy sleep and breathing. While other OSA treatment modalities, such as CPAP, require lifetime use and nightly wear, the Vivos System treatment typically lasts 12 to 24 months, and can allow some patients to avoid further clinical intervention.

“As we strive to bring the Vivos System to more people across the country, thus positively impacting the lives of apnea sufferers and their families, we believe it is critical to bring information about the company to the investing community,” said Huntsman. “That is partly how we will be able to bring relief to millions of OSA patients, both diagnosed and as yet undiagnosed.”

The Vivos System is comprised of Class I and Class II medical devices that are used at the discretion of treating physicians and dentists, based on individual patients’ needs. The Vivos Class II mRNA device received an FDA Clearance on May 8, 2014 via 510k registration with indication for treating nighttime snoring and mild to moderate sleep apnea in adults.

For more information about Vivos, please visit vivoslife.com.

 

 

Media Contact: Shannon Michael, SnappConner PR shannon@snappconner.com